stay up to date on this topic
as family physicians, we’ve seen firsthand the fear and helplessness that the respiratory syncytial virus (rsv) brings to families. it’s the leading cause of infant hospitalizations in canada, with
1 in 50 infants hospitalized during their first year of life. healthy-term babies account for the largest proportion of infants who get sick with severe rsv disease each year. the highest rate of infant hospitalization due to rsv occurs in the first three months of life.
despite its severity, rsv remains largely unknown to the public. until recently, the only preventive option—palivizumab—was limited to high-risk infants, leaving
98 per cent of babies unprotected in many provinces.
breakthrough rsv measures exist, but access depends on where you live
canada now has two newly approved and highly effective tools to prevent rsv in infants: a maternal vaccine known as rsvpref (abrysvo™) and a monoclonal antibody for infants called nirsevimab (beyfortus™). these innovations offer critical protection for infants from rsv starting at birth.
ontario leads the way with full public funding; however, most provinces fall short. for example, alberta and b.c. only offer coverage to high-risk infants, reinforcing a system where location, not health need, dictates protection.
what’s at stake if we don’t act now
at a time when canada’s healthcare system is already under pressure, rsv surges overwhelm paediatric hospitals and delay care. for families, the emotional toll of watching their newborn struggle to breathe is devastating, and difficult for us as healthcare professionals who relive the same preventable scenario each fall.
as rsv season nears, the path forward is clear: act now or repeat a cycle of preventable surges in infants being hospitalized and overwhelmed care systems.